What is AC Immune?
Founded in 2003 and headquartered in Vaud, Switzerland, AC Immune is a specialized biotechnology pharmaceutical firm dedicated to addressing neurodegenerative diseases. The company's focus on this complex area of medicine positions it at the forefront of therapeutic innovation. Its strategic approach involves leveraging cutting-edge research and development to create novel treatments for conditions such as Alzheimer's and Parkinson's disease, aiming to significantly impact patient outcomes and the broader healthcare sector.
How much funding has AC Immune raised?
AC Immune has raised a total of $66M across 1 funding round:
Stock Offering
$66M
Stock Issuance/Offering (2016): $66M, investors not publicly disclosed
What's next for AC Immune?
With the recent enterprise-level backing, AC Immune is strategically positioned for accelerated growth and the advancement of its pipeline. The company is expected to channel these resources into further research and development initiatives, potentially expanding its clinical trial operations and enhancing its manufacturing capabilities. This investment signifies strong confidence in AC Immune's scientific approach and its potential to deliver breakthrough therapies, marking a critical phase in its journey toward commercialization and market leadership in neurodegenerative disease treatment.
See full AC Immune company page
